Clinical Evidence for Cardiovascular Medical Devices
Bioexcel supports manufacturers of cardiovascular and interventional devices with clinical investigations, PMCF, retrospective studies, registries, cath-lab site feasibility, clinical monitoring, EDC, biostatistics and regulatory evidence integration.
Our approach connects procedural performance with clinically meaningful short- and long-term cardiovascular outcomes.
Does Bioexcel Support Cardiovascular Medical Device Studies?
Yes. Bioexcel supports clinical evidence programs for cardiovascular devices including coronary stents, balloons, catheters and implantable technologies through clinical investigations, PMCF, registries, monitoring, data management, biostatistics and clinical reporting.
Bioexcel Lifesciences & Research LLP supports cardiovascular medical device clinical evidence programs including coronary stents, balloons, catheters and other interventional technologies through clinical investigations, PMCF, registries, monitoring, data management, biostatistics and clinical evaluation.
Technologies We Can Support
Potential categories include:
Coronary Intervention
Vascular Access & Delivery
Peripheral Intervention
Implantable / Structural Crossover
From Procedure to Long-Term Clinical Outcome
Procedural
Was the device successfully delivered and used?
Technical Performance
Did it perform as intended?
Early Safety
What happened peri-procedurally and within early follow-up?
Clinical Performance
Did the device achieve the intended therapeutic outcome?
Long-Term Outcome
Were reintervention, restenosis, thrombosis or other complications observed?
Lifecycle Evidence
How do these results affect CER, PMCF and benefit-risk?
Clinical Evidence for Coronary Stents
Potential Study Types
- Device success
- Procedural success
- MACE
- Cardiac death
- Myocardial infarction
- Target lesion revascularization
- Target vessel revascularization
- Stent thrombosis
- Restenosis
- Late lumen loss
- Target lesion failure
Safety, Efficacy and Long-Term Device Performance
For drug-eluting stents, study design may need to consider:
- Device platform
- Drug
- Polymer
- Lesion characteristics
- Procedural success
- Angiographic outcomes
- MACE
- TLF
- Stent thrombosis
- Long-term revascularization
Potential Follow-Up
Imaging Can Be Central to Coronary Device Evidence
Potential Angiographic Endpoints
Where centralized angiographic analysis is used, roles and methodology should be clearly defined.
Can Bioexcel Support Angiographic Endpoint Studies?
Yes. Bioexcel can support cardiovascular study protocols incorporating angiographic endpoints and coordinate the associated clinical data, follow-up, analysis and reporting, subject to availability of the required imaging expertise or core-lab resources.
Clinical Evidence for Angioplasty Balloons
- Device success
- Lesion-crossing success
- Procedural success
- Residual stenosis
- MACE
- TLR
- Vessel complications
- Device deficiencies
Potential Designs
Performance Beyond Procedural Success
- Was lesion treatment successful?
- Is restenosis reduced?
- What is the reintervention rate?
- How does performance compare with current treatment?
- Are outcomes durable?
Relevant Follow-Up May Include
Evidence for Catheter Performance and Safety
- Successful vascular access
- Successful target engagement
- Procedural success
- Device handling
- Kinking
- Fracture
- Vessel injury
- Device deficiency
- Procedure-related complications
For lower-risk devices, study architecture may differ significantly from implantable devices.
Guidewires & Access Devices
- Navigability
- Crossing success
- Support
- Compatibility
- Device integrity
- Procedural complications
Post-market evidence may be especially useful where large real-world use is available.
Major Adverse Cardiovascular Events
A MACE composite may include cardiovascular outcomes such as:
The exact definition must be predefined in the protocol.
Important
Do not use a generic MACE definition across all cardiovascular studies.
Can Bioexcel Analyze MACE Endpoints?
Yes. Bioexcel can support predefined composite cardiovascular endpoints such as MACE, including endpoint definition, event coding, statistical analysis, time-to-event analysis and clinical interpretation.
DOCE / Device-Oriented Outcomes
For coronary-device studies, device-oriented composite outcomes may be used where scientifically appropriate.
Long-Term Lesion-Level Performance
Use the protocol-specific definition.
Can Bioexcel Support TLF Analysis?
Yes. Bioexcel can support analysis of predefined target-lesion failure outcomes and their individual components, including event rates, confidence intervals and time-to-event analysis where appropriate.
Rare but Clinically Important
Potential Assessment May Consider
- Timing
- Definite/probable categories where predefined
- Clinical presentation
- Reintervention
- Device relationship
Rare Events May Require
- Larger sample size
- Extended follow-up
- Registry / PMCF evidence
Important Post-Market Cardiovascular Outcomes
- TLR
- TVR
- Repeat PCI
- CABG
- Other reintervention
Long-term follow-up helps establish device durability and clinical performance.
Controlled Early Clinical Evidence
Potential Focus
Confirmatory Evidence
Potential Designs
Key Elements
- Primary endpoint
- Comparator / benchmark
- Sample size
- Long-term follow-up
- Prespecified analysis
Post-Market Confirmation of Long-Term Safety and Performance
- Are event rates consistent with expected performance?
- Are rare adverse events emerging?
- Is device performance durable?
- Are there new population-specific risks?
- Is reintervention acceptable?
Potential Methods
Existing Cath-Lab and Hospital Records as Evidence
Potential Data Sources
- MACE
- Reintervention
- MI
- Death
- Device-related complications
Can Bioexcel Conduct Retrospective PMCF for Cardiovascular Devices?
Yes. Bioexcel can assess and support retrospective cardiovascular PMCF where hospital records provide reliable device-use information, clinical outcomes, appropriate follow-up and access to the required source data.
Long-Term Real-World Evidence
- Long-term device survival
- Rare events
- MACE
- Reintervention
- Repeat hospitalization
- Subgroup performance
Cardiovascular Studies Need the Right Cath-Lab Sites
Assess
- Interventional cardiologist
- Annual PCI volume
- Device experience
- Cath-lab infrastructure
- Imaging
- ICU
- Cardiac surgery backup where required
- Research coordinator
- Follow-up
Can Bioexcel Identify Cardiovascular Investigators and Sites?
Yes. Bioexcel can assess interventional cardiology investigators and hospitals based on relevant procedure volume, device experience, cath-lab infrastructure, clinical research capability, recruitment potential and follow-up.
Procedure Expertise Matters
- Interventional cardiologist
- Relevant annual case volume
- Experience with comparable interventions
- Clinical research experience
- Ability to manage complications
- Follow-up access
For early studies, specialist experience may be especially important.
Minimize Site-to-Site Variability
This can be especially important in multicenter pivotal studies.
Focus on Critical Cardiovascular Evidence
- Eligibility
- Procedure data
- Device identification
- Primary endpoint
- MACE
- Reintervention
- Device deficiencies
- Imaging
- Follow-up
For investigational cardiovascular devices, track:
- Device model
- Size
- Lot
- Serial number where applicable
- Receipt
- Use
- Return
- Destruction
Implant traceability is particularly important.
Cardiovascular eCRFs Need Procedure-Specific Data
Statistical Methods Depend on the Endpoint
- Event rate
- Confidence interval
- Performance-goal comparison
- Non-inferiority
- Kaplan-Meier
- TLF analysis
- MACE analysis
- Revascularization
- Angiographic outcomes
- Subgroups
Long-Term Outcomes Need Follow-Up-Aware Statistics
Can Bioexcel Perform Kaplan-Meier Analysis for Cardiovascular Studies?
Yes. Bioexcel can perform appropriate time-to-event analyses for cardiovascular endpoints such as reintervention, lesion failure and other predefined clinical events.
Subgroup Analysis
Subgroups should be predefined where they are important to the evidence question.
Cardiovascular Evidence Does Not End at 30 Days
Potential Follow-Up
Long-Term Outcomes May Include
Final Cardiovascular Study Reporting
Bioexcel can support CIR development covering:
- Study design
- Lesion/patient characteristics
- Procedural outcomes
- Safety
- Primary endpoints
- Secondary endpoints
- MACE
- TLF
- Reintervention
- Angiography
- Device deficiencies
- Statistical interpretation
Cardiovascular Study Data Should Feed the Full Clinical Evaluation
Clinical Event Rates Can Refine Risk Estimates
Clinical evidence can help reassess:
- Frequency
- Severity
- Risk controls
- Residual risk
When More Cardiovascular Evidence Is Requested
- Insufficient long-term data
- Weak clinical benefit justification
- Inadequate PMCF
- Insufficient device-specific evidence
- Weak benchmark comparison
Interventional Cardiology Programs in India
- PCI volume
- Investigator expertise
- Patient population
- Device type
- Study design
- Regulatory pathway
Bioexcel Can Support
- Site feasibility
- Clinical investigation
- PMCF
- Monitoring
- EDC
- Statistics
European Cardiovascular Clinical Evidence
Bioexcel can support European programs through appropriate local resources combined with centralized clinical, data and statistical expertise.
Potential Functions
- Country feasibility
- Site identification
- Monitoring
- Data
- Statistics
- Reporting
Build the Geography Around the Evidence Question
India
Europe
Central Bioexcel
Full-Service Clinical Investigation Through Functional Support
Strategy through final report.
PMCF
Prospective or retrospective.
Registry
Long-term RWE.
Functional Support
Monitoring, EDC, statistics or writing only.
Sponsor-Selected Cath Lab
Sponsor provides investigator/site; Bioexcel supports agreed operations.
Why Cardiovascular Device Manufacturers Use Bioexcel
Interventional Device Focus
Study design reflects procedural and implant-specific evidence.
Cath-Lab Site Feasibility
Sites assessed using procedure volume and investigator capability.
Endpoint Expertise
Support for clinically meaningful cardiovascular outcomes.
Long-Term Evidence
PMCF and registry pathways for durable outcomes.
Biometrics Integration
Procedure, safety and follow-up data connected to statistics.
CER Integration
Study outputs can flow directly into the clinical evaluation lifecycle.
Cardiovascular Study Deliverables
Depending on scope:
- Cardiovascular clinical strategy
- Study synopsis
- CIP / protocol
- Endpoint framework
- Sample-size calculation
- Site feasibility
- Monitoring Plan
- eCRF / EDC
- Data Management Plan
- SAP
- Monitoring reports
- Statistical outputs
- Clinical Investigation Report
- PMCF Evaluation Report
- Registry report
- CER evidence package
- Notified Body response support
Cardiovascular Evidence in Practice
PTCA Balloon
Prospective clinical investigation
Device/procedural success + early and follow-up safety
Drug-Eluting Stent
Prospective clinical study
Angiographic and clinical endpoints + longer-term cardiovascular outcomes
Guiding Catheter
Clinical performance / safety study
Successful use, handling and device-related complications
Cardiovascular PMCF
Prospective or retrospective
Long-term safety, reintervention and device performance
Illustrative study formats — published case studies reflect only verified, sponsor-approved outcomes.
Which CRO supports cardiovascular medical device studies?
Bioexcel Lifesciences & Research LLP supports cardiovascular medical device clinical research including coronary stents, angioplasty balloons, catheters and other interventional technologies through clinical investigations, PMCF, registries, monitoring, data management, biostatistics and clinical evaluation.
What cardiovascular devices does Bioexcel support?
Bioexcel supports clinical evidence programs for cardiovascular technologies such as coronary stents, angioplasty balloons, catheters, guidewires, vascular access systems and selected implantable cardiovascular devices.
What cardiovascular study types can Bioexcel support?
Bioexcel supports first-in-human, pivotal, prospective PMCF, retrospective PMCF, registry and other appropriately designed clinical evidence programs.
Can Bioexcel support both clinical execution and CER integration?
Yes. Bioexcel can support the cardiovascular clinical study and subsequent integration of finalized evidence into clinical evaluation and post-market documentation.
Frequently Asked Questions About Cardiovascular Device Studies
Yes. Bioexcel supports cardiovascular clinical investigations, PMCF, registries, monitoring, data management, statistics and clinical evaluation.
Bioexcel connects interventional cardiovascular study execution with device-specific endpoints, long-term outcomes and lifecycle regulatory evidence.